Life expectancy and COVID-19 infection: a population-based cross-sectional study

Background and Objective: Life expectancy and the consequences of its impairment may affect quality of life and suicide. The aim of this study was to assess the impact of COVID-19 on life expectancy in residents of Gonabad city. Methods: This cross-sectional study was conducted on 300 Gonabad residents (general population) from February 2021 to April 2022 using stratified-random sampling method. Data collection was performed through phone interview. Demographic questionnaire and Schneider's life expectancy scale were used. Data analysis was performed using the SPSS software version 23. Findings: Of the 300 participants (53% female and 47% male), 153 were COVID-19 recovered and 147 did not have the history of COVID-19. The average life expectancy score in COVID-19 recovered participants was significantly lower compared to those without the history of COVID-19 (29.17 +or- 5.96 and 31.94+or-4.34, respectively, p=0.001). Also, there was a significant and positive relationship between mean scores of life expectancy and age, gender, education, economic status, the presence of high-risk individuals at home, history of underlying diseases, and smoking (p<0.05). Conclusion: The results of this study stated that life expectancy score in COVID-19 recovered participants was a lower than that of participants without COVID-19 history. Therefore, the role of other variables, including age, gender, and disease history on life expectancy was more prominent on life expectancy in COVID-19 recovered participants.

Evaluation of berberine pellet effect on clinical recovery time in COVID-19 outpatients: a pilot clinical trial

Objective: Severe disease onset of COVID-19 may result in alveolar injury and respiratory failure. Apoptosis and inflammation are the main causes of respiratory distress syndrome. Berberine is used in medicine as an analgesic, anti-asthmatic, anti-inflammatory, and antiviral. In the current investigation, the effect of berberine on COVID-19 outpatients was studied. Materials and Methods: The present clinical trial was performed on 40 outpatients who were randomly assigned to berberine (300 mg, TID, 2 weeks) (n=19) or placebo groups (n=21). Both groups received standard therapy and they were monitored on days 3, 7, and 14 after the beginning of the therapy for clinical symptoms' improvement, quantitative CRP, lymphopenia, CBC, and SpO2. The severity and frequency of these symptoms and the level of the parameters were statistically compared between the two groups. Results: On days 0, 3, 7, and 14, there was no significant difference between the berberine and placebo groups in the improvement of clinical symptoms (cough, shortness of breath, nausea, loss of smell and taste, diarrhea, dizziness, sore throat, stomachache, body aches, and body temperature), quantitative CRP, lymphopenia, WBC, neutrophils, platelets, or SpO2. Conclusion: Berberine (300 mg, TID, two weeks) is ineffective in treating COVID-19. More research with a larger sample size is needed to investigate different berberine dosages in other pharmaceutical formulations.